Mpox booster trial

About the study

The Institute of Tropical Medicine is conducting the mpox booster trial. This research aims to evaluate the duration of immunity following the initial mpox vaccination and to determine if a booster dose is necessary for long-lasting immunity.

Study details

You will be randomly assigned to one of two groups:

• Group 1: You receive a booster dose of the mpox vaccine at the first study visit (intradermal)

• Group: 2: You receive a booster dose of the mpox vaccine at the first study visit (subcutaneous)

• Group 3 (control group): You receive a booster dose of the mpox vaccine 6 months after the first study visit

Study visits

To participate, it is important that you can attend all visits. Each time, you will be required to provide blood samples. The study participation has a duration of approximately 2 years.

• Visits take place at baseline (month 0).

• Afterways, they take place after 1, 3, 6, 12, and 24 months.

Participation criteria

• You are 18 years or older.

• You have previously received the mpox vaccine.

• You have no other vaccinations planned 14 days before or after your first visit.

• You have had no previous mpox infection and no symptoms of a current mpox infection.

• You have had no contact with anyone with active mpox infection 3 weeks prior to the start of the study.

Compensation

Participants receive a fixed compensation of €30 per study visit.

Team

• Principal and Coordinating Investigator: Prof Dr Patrick Soentjens

Questions?

Contact us via studies@itg.be.